메뉴 건너뛰기
The Lancet Neurology
Volumn 13, Issue 1, 2014, Pages 11-13
MS and related disorders: Groundbreaking news
Author keywords

[No Author keywords available]
Indexed keywords

AQUAPORIN 4 ANTIBODY; DACLIZUMAB; ECULIZUMAB; LAQUINIMOD; OCRELIZUMAB; OFATUMUMAB; SIMVASTATIN; VITAMIN D;
EID: 84892165484     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70284-9     Document Type: Note
Times cited : (7)
References (8)
  • 1
    • 84876806691 scopus 로고    scopus 로고
    • Dynamic regulatory network controlling TH17 cell differentiation
    • Wu C, Yosef N, Shalek AK, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496:461-468.
    • (2013) Nature , vol.496 , pp. 461-468
    • Wu, C.1    Yosef, N.2    Shalek, A.K.3
  • 2
    • 84876787121 scopus 로고    scopus 로고
    • Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells
    • Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013, 496:518-522.
    • (2013) Nature , vol.496 , pp. 518-522
    • Kleinewietfeld, M.1    Manzel, A.2    Titze, J.3
  • 3
    • 84887058596 scopus 로고    scopus 로고
    • Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
    • International Multiple Sclerosis Genetics Consortium (IMSGC)
    • Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45:1353-1360. International Multiple Sclerosis Genetics Consortium (IMSGC).
    • (2013) Nat Genet , vol.45 , pp. 1353-1360
    • Beecham, A.H.1    Patsopoulos, N.A.2    Xifara, D.K.3
  • 4
    • 84872768635 scopus 로고    scopus 로고
    • The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS)-a phase II trial
    • Chataway J, Alsanousi A, Chan D, et al. The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS)-a phase II trial. Mult Scler 2012, 18:509.
    • (2012) Mult Scler , vol.18 , pp. 509
    • Chataway, J.1    Alsanousi, A.2    Chan, D.3
  • 6
    • 84877337520 scopus 로고    scopus 로고
    • Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells
    • Najm FJ, Lager AM, Zaremba A, et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nat Biotechnol 2013, 31:426-433.
    • (2013) Nat Biotechnol , vol.31 , pp. 426-433
    • Najm, F.J.1    Lager, A.M.2    Zaremba, A.3
  • 7
    • 84873599764 scopus 로고    scopus 로고
    • Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination
    • Wang S, Bates J, Li X, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 2013, 12:252-264.
    • (2013) Cell Stem Cell , vol.12 , pp. 252-264
    • Wang, S.1    Bates, J.2    Li, X.3
  • 8
    • 84877919003 scopus 로고    scopus 로고
    • Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
    • Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12:554-562.
    • (2013) Lancet Neurol , vol.12 , pp. 554-562
    • Pittock, S.J.1    Lennon, V.A.2    McKeon, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.